Skip to main content
Top
Published in: Hepatology International 1/2012

01-01-2012 | Original Article

Comparison between acetylator phenotype and genotype polymorphism of n-acetyltransferase-2 in tuberculosis patients

Authors: S. V. Rana, R. P. Ola, Sanjeev K. Sharma, S. K. Arora, S. K. Sinha, P. Pandhi, K. Singh

Published in: Hepatology International | Issue 1/2012

Login to get access

Abstract

Background

Isoniazid (INH) is one of the most important drugs of antitubercular treatment regime, and in some cases it causes hepatotoxicity. It is metabolized by hepatic N-acetyltransferase-2 (NAT2).

Aim

To compare whether both methods, i.e., genotype NAT2 and phenotype test of measuring serum INH levels, are useful to identify acetylator status of patients on antitubercular treatment (ATT).

Methods

A total of 251 tuberculosis (TB) patients on standard treatment were followed up to 6 months for this study. NAT2 genotype was assessed by PCR with restriction fragment length polymorphism (RFLP) whereas serum INH levels were measured by fluorometry.

Results

Of the 251 patients, 50 (19.9%) developed ATT-induced hepatotoxicity. By phenotypic estimation, in the hepatotoxicity group, 17/50 (34%) were slow acetylators whereas 33/50 (66%) were fast acetylators. Genotypically, 19/50 (38%) were slow acetylators and 31/50 (62%) fast acetylators. By phenotypic analysis, in non-hepatotoxicity group, 46/201 (22.9%) were slow acetylators and 155/201 (77.1%) fast acetylators. By genotypic analysis, 30/201 (14.9%) were slow acetylators and 171/201 (85%) fast acetylators. Overall, slow acetylators (25.1%) measured phenotypically were not significantly different from slow acetylators (19.5%) measured genotypically.

Conclusion

This study suggests that the acetylator status of TB patients can be detected by phenotypic method as efficaciously as by genotypic method. Therefore, phenotypic method can replace genotypic method to determine acetylating status as phenotypic method is simple and inexpensive.
Literature
1.
2.
go back to reference Hwang SJ, Lee CN, Yen FS, et al. A prospective clinical study of isoniazid–rifampcin–pyrazinamide induced liver injury in an area endemic for hepatitis. Br J Gastroenterol Hepatol 1997;12:87–92CrossRef Hwang SJ, Lee CN, Yen FS, et al. A prospective clinical study of isoniazid–rifampcin–pyrazinamide induced liver injury in an area endemic for hepatitis. Br J Gastroenterol Hepatol 1997;12:87–92CrossRef
3.
go back to reference Tariq S, Khan TS, Malik S, Anwar MS, Rashid A. Frequency of anti-tuberculous therapy-induced hepaptotoxicity in patients and their outcome. J Ayub Med Coll Abbottabad 2009;21:50–52PubMed Tariq S, Khan TS, Malik S, Anwar MS, Rashid A. Frequency of anti-tuberculous therapy-induced hepaptotoxicity in patients and their outcome. J Ayub Med Coll Abbottabad 2009;21:50–52PubMed
4.
go back to reference Huang YS, Chern HD, Su WJ, et al. CytochromeP4502E1 genotype susceptibility to anti-tuberculosis drug induced hepatitis. Herpetology 2003;37:924–930 Huang YS, Chern HD, Su WJ, et al. CytochromeP4502E1 genotype susceptibility to anti-tuberculosis drug induced hepatitis. Herpetology 2003;37:924–930
5.
go back to reference Tsuchida S, Sato K. Glutathione transferases and cancer. Crit Rev Biochem Mol Biol 1992;27:337–384PubMedCrossRef Tsuchida S, Sato K. Glutathione transferases and cancer. Crit Rev Biochem Mol Biol 1992;27:337–384PubMedCrossRef
6.
go back to reference Mitchell JR, Zimmerman HJ, Ishak KG, et al. Isoniazid liver injury: clinical spectrum, pathology and probable pathogenesis. Ann Intern Med 1976;84:181–192PubMed Mitchell JR, Zimmerman HJ, Ishak KG, et al. Isoniazid liver injury: clinical spectrum, pathology and probable pathogenesis. Ann Intern Med 1976;84:181–192PubMed
7.
go back to reference Farrell GC. Drug-induced acute hepatitis. In Farrell GC, editor. Drug-induced liver disease. Churchill Livingstone: Edinburgh; 1994. 247–99. Farrell GC. Drug-induced acute hepatitis. In Farrell GC, editor. Drug-induced liver disease. Churchill Livingstone: Edinburgh; 1994. 247–99.
8.
go back to reference Ryan DE, Ramanathan L, Iida S, et al. Characterization of a major form of rat hepatic microsomal cytochrome P-450 induced by isoniazid. J Bio Chem 1985;260:6385–6393 Ryan DE, Ramanathan L, Iida S, et al. Characterization of a major form of rat hepatic microsomal cytochrome P-450 induced by isoniazid. J Bio Chem 1985;260:6385–6393
9.
go back to reference Tao L, Xiang YB, Wang R, et al. Environmental tobacco smoke in relation to bladder cancer risk—the Shanghai bladder cancer study. Cancer Epidemiol Biomarkers Prev 2010;19:3087–3095PubMedCrossRef Tao L, Xiang YB, Wang R, et al. Environmental tobacco smoke in relation to bladder cancer risk—the Shanghai bladder cancer study. Cancer Epidemiol Biomarkers Prev 2010;19:3087–3095PubMedCrossRef
10.
go back to reference Rabstein S, Brüning T, Harth V, et al. N-acetyltransferase 2, exposure to aromatic and heterocyclic amines, and receptor-defined breast cancer. Eur J Cancer Prev 2010;19:100–109PubMedCrossRef Rabstein S, Brüning T, Harth V, et al. N-acetyltransferase 2, exposure to aromatic and heterocyclic amines, and receptor-defined breast cancer. Eur J Cancer Prev 2010;19:100–109PubMedCrossRef
11.
go back to reference Sun F, Chen Y, Xiang Y, Zhan S. Drug-metabolizing enzyme polymorphism and predisposition to anti-tuberculosis drug induced liver injury: a meta-analysis. Int J Tuberc lung Dis 2008;12:994–1002PubMed Sun F, Chen Y, Xiang Y, Zhan S. Drug-metabolizing enzyme polymorphism and predisposition to anti-tuberculosis drug induced liver injury: a meta-analysis. Int J Tuberc lung Dis 2008;12:994–1002PubMed
12.
go back to reference Huang YS, Chern HD, Su WJ, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor of anti-tuberculosis drug-induced hepatitis. Hepatology 2002;35:883–889PubMedCrossRef Huang YS, Chern HD, Su WJ, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor of anti-tuberculosis drug-induced hepatitis. Hepatology 2002;35:883–889PubMedCrossRef
13.
go back to reference Pande JN, Singh SPN, Khilnani GC, Khilnani S, Tandon RK. Risk factors for hepatotoxicity from antituberculosis drugs: a case–control study. Thorax 1996;51:132–136PubMedCrossRef Pande JN, Singh SPN, Khilnani GC, Khilnani S, Tandon RK. Risk factors for hepatotoxicity from antituberculosis drugs: a case–control study. Thorax 1996;51:132–136PubMedCrossRef
14.
go back to reference Benichou C. Criteria of drug induced liver disorders: reform of international consensus meeting. J Hepatol 1990;11:272–276PubMedCrossRef Benichou C. Criteria of drug induced liver disorders: reform of international consensus meeting. J Hepatol 1990;11:272–276PubMedCrossRef
15.
go back to reference Sud K, Muthukumar T, Singh B, et al. Isoniazid does not affect bioavailability of cyclosporine in renal transplant recipients. Methods Find Exp Clin Pharmacol 2000;22:647–649PubMedCrossRef Sud K, Muthukumar T, Singh B, et al. Isoniazid does not affect bioavailability of cyclosporine in renal transplant recipients. Methods Find Exp Clin Pharmacol 2000;22:647–649PubMedCrossRef
16.
go back to reference Scott EM, Wright RC. Fluorimetric determination of isonicotinic acid hydrazide in serum. J Lab Clin Med 1967;70:353–360 Scott EM, Wright RC. Fluorimetric determination of isonicotinic acid hydrazide in serum. J Lab Clin Med 1967;70:353–360
17.
go back to reference Neughaur S, BabaT Watanabe T, Ishizaki T, Kurokawa K. An early risk marker for diabetic nephropathy in Japanese type 2 diabetic patients. Diabetic Med 1994;11:783–788CrossRef Neughaur S, BabaT Watanabe T, Ishizaki T, Kurokawa K. An early risk marker for diabetic nephropathy in Japanese type 2 diabetic patients. Diabetic Med 1994;11:783–788CrossRef
18.
go back to reference Suzuki H, Morris JS, Li Y, et al. Interaction of the cytochrome P4501A2, SULT1A1 and NAT gene polymorphisms with smoking and dietary mutagen intake in modification of the risk of pancreatic cancer. Carcinogenesis 2008;29:1184–1191PubMedCrossRef Suzuki H, Morris JS, Li Y, et al. Interaction of the cytochrome P4501A2, SULT1A1 and NAT gene polymorphisms with smoking and dietary mutagen intake in modification of the risk of pancreatic cancer. Carcinogenesis 2008;29:1184–1191PubMedCrossRef
19.
go back to reference Rana SV, Pal R, Vaiphei K, Ola RP, Singh K. Hepatoprotection by carotenoids in isoniazid-rifampicin induced hepatic injury in rats. Biochem Cell Biol 2010;88:819–834PubMedCrossRef Rana SV, Pal R, Vaiphei K, Ola RP, Singh K. Hepatoprotection by carotenoids in isoniazid-rifampicin induced hepatic injury in rats. Biochem Cell Biol 2010;88:819–834PubMedCrossRef
20.
21.
go back to reference Mahmood K, Hussain A, Jairmani KL, et al. Hepatotoxicity with anti-tuberculosis drugs: the risk factors. Pak J Med Sci 2007;23:33–38 Mahmood K, Hussain A, Jairmani KL, et al. Hepatotoxicity with anti-tuberculosis drugs: the risk factors. Pak J Med Sci 2007;23:33–38
22.
go back to reference Ohno M, Yamaguchi I, Yamamoto I, et al. Slow N-acetyltransferase 2 genotype affects the incidence of INH and RMP induced hepatotoxicity. Intl J Tuberc Lung Dis 2000;4:256–261 Ohno M, Yamaguchi I, Yamamoto I, et al. Slow N-acetyltransferase 2 genotype affects the incidence of INH and RMP induced hepatotoxicity. Intl J Tuberc Lung Dis 2000;4:256–261
23.
go back to reference Doll Ma, Fretland AJ, Deitz AC, Hein W. Determination of human NAT2 acetylator genotype by restriction fragment length polymorphism and allele- specific amplification. Anal Biochem 1995;231:413–418PubMedCrossRef Doll Ma, Fretland AJ, Deitz AC, Hein W. Determination of human NAT2 acetylator genotype by restriction fragment length polymorphism and allele- specific amplification. Anal Biochem 1995;231:413–418PubMedCrossRef
24.
go back to reference Freguson RJ, Doll MA, Rustan TD, Gray K, Hein DW. Cloning, expression and functional characterization of two mutant (NAT2–191and NAT2–341/803) and wild-type human polymorphic N-acetyltransferase (NAT2) alleles. Drug Metabol Dispos 1994;22:371–376 Freguson RJ, Doll MA, Rustan TD, Gray K, Hein DW. Cloning, expression and functional characterization of two mutant (NAT2–191and NAT2–341/803) and wild-type human polymorphic N-acetyltransferase (NAT2) alleles. Drug Metabol Dispos 1994;22:371–376
25.
go back to reference Parthasarthy R, Sarma GR, Janardhanam B, et al. Hepatic toxicity in south Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. Tubercule 1986;67:99–108CrossRef Parthasarthy R, Sarma GR, Janardhanam B, et al. Hepatic toxicity in south Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. Tubercule 1986;67:99–108CrossRef
26.
go back to reference Gurumurthi P, Kirshnamurthy MS, Nazareth O, et al. Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand south Indian patients during treatment with isoniazid for tuberculosis. Am Rev Respir Dis 1984;129:58–61 Gurumurthi P, Kirshnamurthy MS, Nazareth O, et al. Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand south Indian patients during treatment with isoniazid for tuberculosis. Am Rev Respir Dis 1984;129:58–61
27.
go back to reference Vatsis KP, Weber WW, Bel DA, et al. Nomenclature for N-acetyltransferase genetic polymorphism of cytochrome P4502E1 in Swedish population. Relationship to incidence of lung cancer. Pharmacogenesis 1995;5:1–20CrossRef Vatsis KP, Weber WW, Bel DA, et al. Nomenclature for N-acetyltransferase genetic polymorphism of cytochrome P4502E1 in Swedish population. Relationship to incidence of lung cancer. Pharmacogenesis 1995;5:1–20CrossRef
28.
go back to reference Bose PD, Sarma MP, Medhi S, et al. Role of polymorphic N-acetyl transferase 2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis. J Gastroenterology and Hepatology 2011;26:312–318CrossRef Bose PD, Sarma MP, Medhi S, et al. Role of polymorphic N-acetyl transferase 2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis. J Gastroenterology and Hepatology 2011;26:312–318CrossRef
29.
go back to reference Díaz-Molina R, Cornejo-Bravo JM, Ramos-Ibarra MA. Genotypye and phenotype of NAT2 and the occurrence of adverse drug reaction in Mexican individuals to an isonizid-based prophylactic chemotherapy for tuberculosis. Mol Med Rep 2008;1:875–879 Díaz-Molina R, Cornejo-Bravo JM, Ramos-Ibarra MA. Genotypye and phenotype of NAT2 and the occurrence of adverse drug reaction in Mexican individuals to an isonizid-based prophylactic chemotherapy for tuberculosis. Mol Med Rep 2008;1:875–879
30.
go back to reference Singh N, Dubey S, Chinnaraj S, Golani A, Maitra A. Study of NAT2 gene polymorphisms in an Indian population: association with plasma isoniazid concentration in a cohort of tuberculosis patients. Mol Diag Ther 2009;13:49–58 Singh N, Dubey S, Chinnaraj S, Golani A, Maitra A. Study of NAT2 gene polymorphisms in an Indian population: association with plasma isoniazid concentration in a cohort of tuberculosis patients. Mol Diag Ther 2009;13:49–58
Metadata
Title
Comparison between acetylator phenotype and genotype polymorphism of n-acetyltransferase-2 in tuberculosis patients
Authors
S. V. Rana
R. P. Ola
Sanjeev K. Sharma
S. K. Arora
S. K. Sinha
P. Pandhi
K. Singh
Publication date
01-01-2012
Publisher
Springer-Verlag
Published in
Hepatology International / Issue 1/2012
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-011-9309-4

Other articles of this Issue 1/2012

Hepatology International 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.